19th Ave New York, NY 95822, USA

Treatments

Treatments

nice.org.uk

COVID-19 rapid guideline: managing COVID-19

Source: NICE

This guideline covers the management of COVID-19 for children, young people and adults in all care settings. It brings together our existing recommendations on managing COVID-19, and new recommendations on...

thelancet.com

COVID-19 and the effects on pulmonary function following infection: A retrospective analysis

Source: Lancet

Peer review article This study showed that there is no difference in pulmonary function as measured by function tests before and after COVID-19 infection in non-critically ill classified patients. There...

thelancet.com

Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial

Source: Lancet

Peer review article Inhaled budesonide (steroid) improves time to recovery, with a chance of also reducing hospital admissions or deaths (although did not meet the 95% certainty level of proof),...

thelancet.com

Awake prone positioning for COVID-19 acute hypoxaemic respiratory failure: a randomised, controlled, multinational, open-label meta-trial

Source: Lancet

Peer revie article Awake prone positioning of patients with hypoxaemic respiratory failure due to COVID-19 reduces the incidence of treatment failure and the need for intubation without any signal of...

bmj.com

Covid-19: UK approves first monoclonal antibody treatment

Source: BMJ

The UK’s drug regulator has approved the first monoclonal antibody (lab-grown antibodies) treatment—Ronapreve, a combination of casirivimab and imdevimab—for the treatment and prevention of acute Covid-19 in adults

who.int

Medical Product Alert N°4/2021: Falsified remdesivir

Source: WHO

This WHO Medical Product Alert refers to two batches of falsified remdesivir (antiviral drug) injection 100mg/20ml (5mg/ml)identified in the WHO Region of the Americas and reported to WHO in July...

jwatch.org

Further Evidence that Remdesivir Has Limited Benefit for Patients Hospitalized with COVID-19

Source: NEJM

Report on peer review article More than a year into the pandemic, our most efficacious “antiviral” treatment remains monoclonal antibodies(made outside of the body) — and this study further demonstrates...

africacheck.org

No proof Mega Oxygen boosts oxygen levels or cures Covid-19, as viral Facebook video claims

Source: Africa check

Claim: A video on Facebook claims that Mega Oxygen, with magnesium peroxide as an ingredient, boosts oxygen levels in the body and heals Covid-19. Medical experts said scientific evidence did...

africacheck.org

Beware! Details in viral message about Discovery Health and oxygen tanks for Covid-19 patients misleading and dangerous

Source: Africa check

The WHO recommends that patients with oxygen levels lower than 90% should contact their doctor and go to hospital, not seek treatment at home.

nejm.org

Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia

Source: NEJM

Peer review article Among patients hospitalized with Covid-19 pneumonia, tofacitinib (an arthritis drug) led to a lower risk of death or respiratory failure through day 28 than placebo.

nejm.org

Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19

Source: NEJM

Peer review article Among high-risk walking patients, bamlanivimab (a lab made antibody) plus etesevimab (a lab made antibody) led to a lower incidence of Covid-19–related hospitalization and death than did...

thelancet.com

The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study

Source: Lancet

Peer review article Antibody production after a single dose of BNT162b2 (Pfizer-BioNTech) is impaired by methotrexate (an immune system suppressant) normal cellular responses are preserved. Antibody development alone might not...

thelancet.com

Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial

Source: Lancet

Peer review article In patients with mild-to-moderate COVID-19 managed without hospital admission, adding azithromycin (an antibiotic) to standard care treatment did not reduce the risk of subsequent hospital admission or...

thelancet.com

Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial

Source: Lancet

Peer review article In patients with cardiometabolic risk factors (those which affect their chances of having a heart attack) who were hospitalised with COVID-19, treatment with dapagliflozin (a medicine to...

thelancet.com

Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial

Source: Lancet

Peer review article In patients with suspected COVID-19 in the community in the UK, who were at high risk of adverse outcomes, treatment with doxycycline (an antibiotic) was not associated...

bmj.com

Covid-19: NICE issues guidance on vaccine induced immune thrombocytopenia and thrombosis

Source: BMJ

Patients who are acutely unwell with suspected vaccine induced immune thrombocytopenia and thrombosis (VITT) should be referred immediately to the emergency department, says new rapid guidance from the National Institute...

who.int

WHO recommends life-saving interleukin-6 receptor blockers for COVID-19 and urges producers to join efforts to rapidly increase access

Source: WHO

The World Health Organization (WHO) has updated its patient care guidelines to include interleukin-6 receptor blockers, a class of medicines that are lifesaving in patients who are severely or critically...

who.int

The WHO and Angry Birds Friends encourage communities to stay active during COVID-19

Source: WHO

. Over the last year, however, many people are staying home and leading a more sedentary life due to COVID-19. To help raise awareness on the benefits of physical activity...

afro.who.int

WHO statement on the clinical trial of CVO+ remedy

Source: WHO Africa

The World Health Organization (WHO) reiterates that there is not yet a specific antiviral treatment whose safety and effectiveness are proven to treat COVID-19. Corticosteroids and medical oxygen remain essential...

afro.who.int

Home-based care boosts Nigeria’s COVID-19 fight

Source: WHO Africa

“Home-Based Care (where people with COVID-19 receive care in their own homes) has not only helped to reduce the strain on local government resources, but also to alleviate fear and...

NEJM

Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia

Source: 7/29/21

Peer review article Among patients hospitalized with Covid-19 pneumonia, tofacitinib (an arthritis drug) led to a lower risk of death or respiratory failure through day 28 than placebo.

NEJM

Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19

Source: 7/14/21

Peer review article Among high-risk walking patients, bamlanivimab (a lab made antibody) plus etesevimab (a lab made antibody) led to a lower incidence of Covid-19–related hospitalization and death than did...

Lancet

The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study

Source: 7/8/21

Peer review article Antibody production after a single dose of BNT162b2 (Pfizer-BioNTech) is impaired by methotrexate (an immune system suppressant) normal cellular responses are preserved. Antibody development alone might not...

Lancet

Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial

Source: 7/9/21

Peer review article In patients with mild-to-moderate COVID-19 managed without hospital admission, adding azithromycin (an antibiotic) to standard care treatment did not reduce the risk of subsequent hospital admission or...

Lancet

Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial

Source: 7/21/21

Peer review article In patients with cardiometabolic risk factors (those which affect their chances of having a heart attack) who were hospitalised with COVID-19, treatment with dapagliflozin (a medicine to...

Lancet

Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial

Source: 7/27/21

Peer review article In patients with suspected COVID-19 in the community in the UK, who were at high risk of adverse outcomes, treatment with doxycycline (an antibiotic) was not associated...

BMJ

Covid-19: NICE issues guidance on vaccine induced immune thrombocytopenia and thrombosis

Source: 7/29/21

Patients who are acutely unwell with suspected vaccine induced immune thrombocytopenia and thrombosis (VITT) should be referred immediately to the emergency department, says new rapid guidance from the National Institute...

WHO

WHO recommends life-saving interleukin-6 receptor blockers for COVID-19 and urges producers to join efforts to rapidly increase access

Source: 7/6/21

The World Health Organization (WHO) has updated its patient care guidelines to include interleukin-6 receptor blockers, a class of medicines that are lifesaving in patients who are severely or critically...

WHO

The WHO and Angry Birds Friends encourage communities to stay active during COVID-19

Source: 7/26/21

. Over the last year, however, many people are staying home and leading a more sedentary life due to COVID-19. To help raise awareness on the benefits of physical activity...

WHO Africa

WHO statement on the clinical trial of CVO+ remedy

Source: 7/5/21

The World Health Organization (WHO) reiterates that there is not yet a specific antiviral treatment whose safety and effectiveness are proven to treat COVID-19. Corticosteroids and medical oxygen remain essential...

WHO Africa

Home-based care boosts Nigeria’s COVID-19 fight

Source: 7/15/21

“Home-Based Care (where people with COVID-19 receive care in their own homes) has not only helped to reduce the strain on local government resources, but also to alleviate fear and...

NEJM

Further Evidence that Remdesivir Has Limited Benefit for Patients Hospitalized with COVID-19

Source: 8/3/21

Report on peer review article More than a year into the pandemic, our most efficacious “antiviral” treatment remains monoclonal antibodies(made outside of the body) — and this study further demonstrates...

fullfact.org

Hydroxychloroquine study not all that it seems

Source: Fullfact

Claim: A new study shows hydroxychloroquine can increase Covid-19 survival rates by 200%. Verdict: False. This very small study has not been peer-reviewed and it does not show that hydroxychloroquine...

jwatch.org

Therapeutic Doses of Anticoagulation Did Not Benefit Patients with COVID-19 and Elevated D-Dimer Levels

Source: NEJM

Based on this well-designed study in patients with elevated D-dimer levels, there is no indication for using therapeutic anticoagulation dosing for clotting event preventative measures in patients with COVID-19.

thelancet.com

Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study

Source: Lancet

Single-dose vaccination with Pfizer and AstraZeneca vaccines provide substantial protection against infection in older adults from 4–7 weeks after vaccination and might reduce SARS-CoV-2 transmission.

cdc.gov

Symptoms of Depression, Anxiety, Post-Traumatic Stress Disorder, and Suicidal Ideation Among State, Tribal, Local, and Territorial Public Health Workers During the COVID-19 Pandemic — United States, March–April 2021

Source: US CDC

Implementing prevention and control practices that eliminate, reduce, and manage factors that cause or contribute to public health workers’ poor mental health might improve mental health outcomes during emergencies.

africacdc.org

Africa CDC and the Ministry of Public Health strengthen the capacities of Cameroonian clinicians in COVID-19 case management

Source: Africa CDC

Building the capacity of health workers in case management is one of the factors that will help minimize deaths and complications from COVID-19.

nejm.org

Adjunct Immune Globulin for Vaccine-Induced Thrombotic Thrombocytopenia

Source: NEJM

The use of high-dose intravenous immune globulin (IVIG) plus anticoagulation is recommended for the treatment of vaccine-induced immune thrombotic thrombocytopenia (VITT), a rare side effect of adenoviral vector vaccines against...

thelancet.com

Anticoagulation in COVID-19: reaction to the ACTION trial

Source: Lancet

In these primarily stable hospitalised patients, therapeutic dose rivaroxaban in hospital with post-discharge treatment up to 30 days conferred no additional benefit when compared with in-hospital prophylactic-dose heparin.

thelancet.com

Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial

Source: Lancet

Discontinuation of RAS-inhibition (renin-angiotensin-system inhibitor - a protein that helps regulate the concentration of blood) in COVID-19 had no significant effect on the maximum severity of COVID-19 but may lead...

bmj.com

Covid-19: Aspirin does not improve survival for patients admitted to hospital, trial reports

Source: BMJ

Aspirin does not improve survival for patients in hospital with Covid-19, the UK Recovery trial1 has reported.

cdc.gov

Clinical Care for Specific Patient Types in context of COVID-19

Source: US CDC

An update on guidance for children, newborns, pregnant or breastfeeding patients and links to family planning advice and advice for people with underlying medical conditions.

who.int

Blood donation during Covid-19 Pandemic

Source: WHO

During the unprecedented COVID-19 pandemic, UBTS experienced a shortage of blood supplies and had to use innovative ways of mobilizing blood donors.

nejm.org

Adjunct Immune Globulin for Vaccine-Induced Thrombotic Thrombocytopenia

Source: NEJM

The use of high-dose intravenous immune globulin (IVIG) plus anticoagulation is recommended for the treatment of vaccine-induced immune thrombotic thrombocytopenia (VITT), a rare side effect of adenoviral vector vaccines against...

thelancet.com

Anticoagulation in COVID-19: reaction to the ACTION trial

Source: Lancet

In these primarily stable hospitalised patients, therapeutic dose rivaroxaban in hospital with post-discharge treatment up to 30 days conferred no additional benefit when compared with in-hospital prophylactic-dose heparin.

thelancet.com

Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial

Source: Lancet

Discontinuation of RAS-inhibition (renin-angiotensin-system inhibitor - a protein that helps regulate the concentration of blood) in COVID-19 had no significant effect on the maximum severity of COVID-19 but may lead...

bmj.com

Covid-19: Aspirin does not improve survival for patients admitted to hospital, trial reports

Source: BMJ

Aspirin does not improve survival for patients in hospital with Covid-19, the UK Recovery trial1 has reported.

cdc.gov

Clinical Care for Specific Patient Types in context of COVID-19

Source: US CDC

An update on guidance for children, newborns, pregnant or breastfeeding patients and links to family planning advice and advice for people with underlying medical conditions.

who.int

Blood donation during Covid-19 Pandemic

Source: WHO

During the unprecedented COVID-19 pandemic, UBTS experienced a shortage of blood supplies and had to use innovative ways of mobilizing blood donors.

jwatch.org

Is Methylprednisolone Better than Dexamethasone for Severe COVID-19?

Source: NEJM

We're now seeing fewer and fewer patients admitted with severe COVID-19, but some patients with the severe disease still could benefit from this adjusted approach to steroid therapy.

jwatch.org

In a Large Randomized Trial, Convalescent Plasma Strikes Out

Source: NEJM

As this large, randomized trial does not demonstrate a survival benefit of using blood plasma from patients who have recovered from COVID-19 in hospitalized patients with COVID-19, the findings should...

nice.org.uk

COVID-19 rapid guideline: managing COVID-19

Source: NICE

On 3 June 2021, they added new recommendations on azithromycin (an antibiotic) to treat COVID-19. Do not use this drug on COVID-19 patients.

thelancet.com

Convalescent plasma transfusion for pregnant patients with COVID-19

Source: Lancet

This report suggests that pregnant women with no detectable anti-SARS-CoV-2 antibodies are potential candidates for treatment with convalescent plasma with high antibody titres in an early stage of the disease,

thelancet.com

Low-value medical care in the pandemic—is this what the doctor ordered?

Source: Lancet

There is an urgent need for democratising evidence-informed medicine in India. Clinical guidelines should be based on evidence, responsive to local resources, and include a broad range of stakeholders, including...

thelancet.com

Repurposing drugs for treatment of COVID-19

Source: Lancet

A central data repository called the CORONA Project was launched in early 2020 to track all treatments that have been used for Covid-19.

thelancet.com

Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial

Source: Lancet

Use of therapeutic-dose rivaroxaban, and other direct oral anticoagulants, should be avoided in patients in the absence of an evidence-based reason to prescribe oral anti-clotting drugs.

poynter.org

There’s no proof that hydroxychloroquine or ivermectin caused a drop in cases in India

Source:

The post was flagged as part of Facebook’s efforts to combat false news and misinformation on its News Feed. Bothy drugs have been repeatedly tested and have been found to...

nice.org.uk

COVID-19 rapid guideline: managing COVID-1

Source: NICE

This guideline brings together NICE's existing recommendations on managing COVID-19, and new recommendations on therapeutics, so that healthcare staff and those planning and delivering services can find and use them...

thelancet.com

Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial

Source: Lancet

Given the absence of orally administered therapies to prevent COVID-19 complications in community-treated patients and the benefit of colchicine in patients with PCR-proven COVID-19, this safe and inexpensive anti-inflammatory agent...

thelancet.com

Laboratory trends, hyperinflammation, and clinical outcomes for patients with a systemic rheumatic disease admitted to hospital for COVID-19: a retrospective, comparative cohort study

Source: Lancet

Patients with a systemic rheumatic disease who were admitted to the hospital for COVID-19 had increased risk for hyper inflammation, kidney injury, admission to IC, and mechanical ventilation compared with...

fullfact.org

Freedom March video littered with false claims about Covid-19 cures

Source: Full Fact

Claim:: Vitamin D, Ivermectin, zinc and hydroxychloroquine are safe and effective treatments for Covid-19. Verdict: There is no robust evidence yet that any of these can treat or prevent Covid

nejm.org

PF4 Immunoassays in Vaccine-Induced Thrombotic Thrombocytopenia

Source: NEJM

An algorithm for the management of this syndrome was proposed on the basis of immunoassays detecting anti–PF4–heparin antibodies - which in turn could predict the clottiong events.

nice.org.uk

COVID-19 rapid evidence summary: Long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19

Source: NICE

There is no evidence to suggest that people taking NSAIDs for a long-term condition should be advised to stop treatment in the context of COVID‑19.

nice.org.uk

COVID 19 rapid evidence summary: Anakinra for COVID-19 associated secondary haemophagocytic lymphohistiocytosis

Source: NICE

At this time, policy decisions on whether anakinra (arthritis drug) should be used for treating COVID-19 associated inflamatory conditions will need to consider data extrapolated from studies assessing anakinra for...

nice.org.uk

COVID-19 rapid evidence summary: angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in people with or at risk of COVID-19

Source: NICE

Conclusions cannot be drawn on whether ACEIs (drugs involved in contracting blood vessels) or ARBs (drugs that reduce blood pressure) increase the risk of developing COVID-19 or developing more severe...

thelancet.com

Immunotherapy in COVID-19: why, who, and when?

Source: Lancet

Unsurprisingly, given human genetic variation and the burgeoning genetic variance of the virus itself, evidence for the efficacy of many interventions is unclear.

fullfact.org

Viral video spreads misinformation about ethylene oxide and Ivermectin

Source: Full Fact

Overexposure to ethylene oxide itself can cause health problems such as cancer, but there is no suggestion that using something that has been sterilised by ethylene oxide is harmful.

fullfact.org

Honey, ginger and pepper isn’t approved treatment for Covid-19

Source: Full Fact

WHAT WAS CLAIMED: Honey, pepper and ginger can ‘100%’ eliminate the effect of Covid-19 and has been approved by the WHO.

jwatch.org

Largest Randomized Tocilizumab Trial Shows Mortality Reduction

Source: NEJM

Report on peer review article These latest results support the use of tocilizumab in combination with dexamethasone in recently hospitalized patients with progressive COVID-19.

thelancet.com

Inhaled budesonide for early treatment of COVID-19

Source: The Lancet

The use of inhaled anti inflamitary treatment (corticosteroid) might be associated with poor outcomes among people being treated for COVID-19 in hospital.

thelancet.com

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform tria

Source: The Lancet

Peer review article: In patients hospitalised with COVID-19, plasma taken from people who had recovered from COVID-19 did not improve survival or other prespecified clinical outcomes.

thelancet.com

Cytokine adsorption during ECMO for COVID-19-related ARDS

Source: The Lancet

Report on peer review article: The study highlights the potential risks of cytokine adsorption (proteins being made by cells and entering other cell to communicate) in patients receiving oxygen therapy...

thelancet.com

Convalescent plasma in patients hospitalised with COVID-19

Source: The Lancet

Opinion piece: Following initial reports, a series of peer-reviewed randomised trials did not confirm the positive findings

bmj.com

Use of repurposed and adjuvant drugs in hospital patients with covid-19: multinational network cohort study

Source: BMJ

Peer review article: Hydroxychloroquine, azithromycin, lopinavir-ritonavir, and umifenovir were the most prescribed repurposed drugs. Antithrombotics, antibiotics, H2 receptor antagonists) , and corticosteroids were often used as supplemental treatments.

thelancet.com

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Source: The Lancet

In hospitalised COVID-19 patients suffering from lack of oxygen to body tissues and systemic inflammation, tocilizumab (a drug mainly used for the treatment of rheumatoid arthritis) improved survival and other...

thelancet.com

3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study

Source: The Lancet

Findings highlight the importance of respiratory follow-up of patients with COVID-19, and that studies to mitigate the long-term consequences of COVID-19 pneumonia, including pulmonary rehabilitation as well as novel therapeutic...

thelancet.com

Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study

Source: The Lancet

Non-steroidal anti-inflammatory drugs (NSAID) use is not associated with higher mortality or increased severity of COVID-19. Policymakers should consider reviewing issued advice around NSAID prescribing and COVID-19 severity.

thelancet.com

The Berlin definition of acute respiratory distress syndrome: should patients receiving high-flow nasal oxygen be included?

Source: The Lancet

Since 2015, high-flow nasal oxygen has become widely used as effective therapeutic support for acute respiratory failure, most recently in patients with severe COVID-19.

thelancet.com

Interleukin-6 receptor blockade in patients with COVID-19: placing clinical trials into context

Source: The Lancet

Timing from clinical presentation to treatment, severity of illness, and concomitant use of corticosteroids are among the factors that might have contributed to apparently inconsistent results.

thelancet.com

COVID-19 in patients with rheumatic disease: finally, a denominator

Source: The Lancet

The timing of therapy in COVID-19 is undoubtedly crucial, but outstanding questions include whether certain therapies for rheumatic disease, such as interleukin-6 and Janus kinase 1 inhibition should be used...

thelancet.com

Tocilizumab in COVID-19: some clarity amid controversy

Source: The Lancet

Preliminary reports were followed by large observational studies in critically ill patients with COVID-19, which suggested a mortality benefit (difference in mortality between treated and untreated patients) with tocilizumab.

thelancet.com

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Source: The Lancet

In hospitalised COVID-19 patients with hypoxia (oxygen deprivation to body tissues) and systemic inflammation, tocilizumab (a drug commonly used for arthritis) improved survival and other clinical outcomes. These benefits were...

bmj.com

Covid-19: Countries rally to support India through “storm that has shaken the nation”

Source: BMJ

Countries have pledged to help India as the country continues to see an exponential rise in COVID-19 cases and deaths, with hospitals running out of oxygen, drugs, and beds.

bmj.com

Covid-19: Heavy use of oxygen brings new danger to world’s hospitals

Source: BMJ

A total of 82 people were left dead and 110 injured from a hospital fire on 24 April in Baghdad, Iraq, which began with an explosion caused by a fault...

jwatch.org

COVID-19: Reinfection Risk / Bamlanivimab Authorization Revoked

Source: NEJM

A study in The Lancet Respiratory Medicine helps characterize the risk for SARS-CoV-2 reinfection in a close contact setting.

thelancet.com

Extracorporeal membrane oxygenation network organisation and clinical outcomes during the COVID-19 pandemic in Greater Paris, France: a multicentre cohort study

Source: Lancet

Early reports from China on the use of ECMO in COVID-19-associated ARDS indicated unfavourable outcomes.

jwatch.org

COVID-19: Antibody Duo Helps Prevent Infection / B.1.1.7 Variant Not Linked to More Severe Disease

Source: NEJM

Regeneron's casirivimab-imdevimab monoclonal antibody combination cut the risk for symptomatic SARS-CoV-2 infection in household contacts of COVID-19 patients by 81%.

jwatch.org

Prophylaxis Against Venous Thromboembolism in ICU Patients with COVID-19

Source: NEJM

This evidence — along with other interim trial data suggesting probable harm from therapeutic anticoagulation (a means of preventing blood clots) in severely ill patients with COVID-19 — should lead...

thelancet.com

Report on peer review article

Source: The Lancet

Earlier studies in vitro and in mice demonstrated a broad potent antiviral effect of niclosamide against SARS-CoV-2 and other viruses.

thelancet.com

Effects of a multi-faceted education and support programme on anxiety symptoms among people with systemic sclerosis and anxiety during COVID-19 (SPIN-CHAT): a two-arm parallel, partially nested, randomised, controlled trial

Source: The Lancet

The intervention (Scleroderma Patient-centred Intervention Network COVID-19 Home-isolation Activities Together (SPIN-CHAT) Program) did not significantly improve anxiety symptoms or other mental health outcomes post-intervention. However, anxiety and depression symptoms were...

bmj.com

Covid-19: Budesonide shortens recovery time in patients not admitted to hospital, study finds

Source: BMJ

Inhaled budesonide, a common corticosteroid used to treat asthma and chronic obstructive pulmonary disease, can shorten the time it takes for people not admitted to hospital to recover from COVID-19...

jwatch.org

COVID-19: Double-Masking / Bamlanivimab-Etesevimab EUA / Ventilator Splitter Recommendations / Remdesivir Guidance

Source: NEJM

Discussion of research articles The Annals of Internal Medicine have further reduced their advice on using Remdesivir as a treatment for COVID-19. The FDA has granted an emergency use authorization...

thelancet.com

Oxygen supplies and COVID-19 mortality in Africa

Source: The Lancet

Opinion piece Medical oxygen is becoming a critical need as the second wave of COVID-19 unfolds in Africa and health-care systems risk becoming overwhelmed with patients, the Africa Centres for...

thelancet.com

A simple nomogram for predicting failure of non-invasive respiratory strategies in adults with COVID-19: a retrospective multicentre study

Source: The Lancet

Research article By identifying patients at risk of NIRS (Non-invasive respiratory strategies) failure, clinicians could ascertain those who might benefit from early monitoring and early interventions.  However, any benefits from...

bmj.com

Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: cohort study

Source: BMJ

Peer Reviewed paper Early initiation of prophylactic anticoagulation (drugs that help to stop blood from clotting) compared with no anticoagulation among patients admitted to hospital with Covid-19 was associated with...

jwatch.org

COVID-19: Eye Abnormalities / Pulse Oximetry Accuracy & Skin Pigmentation

Source: NEJM

Comment on pre-release Researchers studied nearly 130 patients hospitalized with severe COVID-19 who had undergone brain MRI. Some 7% of patients had one or more nodules in the light receptor...

thelancet.com

Tuberculosis preventive therapy for children and adolescents: an emergency response to the COVID-19 pandemic

Source: The Lancet

COVID-19, the clinical syndrome caused by SARS-CoV-2, has caused a tremendous burden of global morbidity and mortality. COVID-19 is predicted to have a devastating impact on other global infections, most...

bmj.com

Prophylactic anticoagulation for patients in hospital with covid-19

Source: BMJ

Report on research article Recent retrospective data showing low rates of hospital associated internal bleeding post-discharge are reassuring, Randomised trials formally evaluating the need for extended blood clot prevention are...

cdc.gov

Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease (COVID-19)

Source: US CDC

This document provides guidance on caring for patients infected with SARS-CoV-2, the virus that causes COVID-19

who.int

G7 leaders commit US$ 4.3 billion to finance global equitable access to tests, treatments and vaccines in 2021

Source: WHO

Commitments made at today’s Virtual G7 leaders meeting hosted by UK Prime Minister Boris Johnson, and at the Munich Security Conference later in the day, signalled significant progress in the...

fullfact.org

The link between vitamin D and Covid-19 is complex

Source: FullFact

Claim:  The death rate in Andalucía almost halved between November and December following the introduction of their vitamin D policy. Verdict: The death rate in Andalucía did drop, but numbers...

jwatch.org

WHO Recommends Against Hydroxychloroquine for COVID-19 Prevention

Source: NEJM

Report on peer review article The WHO recommendation against Hydroxychloroquine for COVID-19 prevention, published in The BMJ, is based on a meta-analysis of six randomized trials comprising over 6000 people...

jwatch.org

COVID-19: Ivermectin & Mild Illness / Seroprevalence in Children / Conjunctival Swabs? / Cardiac Screening in Pro Athletes

Source: NEJM

Report on the ineffectiveness of using the drug Ivermectin to treat mild COVID-19 symptoms. Review of the effects of the virus causing cardiological issues after infection in 4% of those...

thelancet.com

Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity

Source: The Lancet

Peer review article Research results suggest that SARS-CoV-2 can use TMPRSS2 (a protein normally found in the membrane of human cells) and closely related proteases for spread in the upper...

thelancet.com

Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial

Source: The Lancet

Peer review article This trial did not show efficacy of sarilumab in patients admitted to hospital with COVID-19 and receiving supplemental oxygen. Adequately powered trials of targeted immunomodulatory therapies assessing...

thelancet.com

Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC)

Source: The Lancet

Peer review article Routine use of tocilizumab in patients admitted to hospital with moderate to severe COVID-19 is not supported. However, post-hoc evidence from this study suggests tocilizumab might still...

thelancet.com

Interferon antagonism by SARS-CoV-2: a functional study using reverse genetics

Source: The Lancet

Peer review article The SARS-CoV-2 viruses share a set of proteins and use the same cellular entry receptor, but their transmission efficiencies and pathogenetic traits differ. This study looks at...

thelancet.com

Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial

Source: The Lancet

Peer reviewed article Taken together, the findings plus the evidence to date suggest that azithromycin is not a sufficiently effective treatment to justify routine use for treatment of COVID-19, neither...

thelancet.com

IL-6 blockade for COVID-19: a global scientific call to arms

Source: The Lancet

Opinion piece Accepting that IL-6 blockade reduces mortality in patients the question will inevitably become which populations are most likely to benefit. The absolute risk reduction (and corresponding number needed...

thelancet.com

COVID-19 and inhaled corticosteroids—another piece in an expanding puzzle

Source: The Lancet

Opinion piece The role of inhaled corticosteroids in the prevention and treatment of COVID-19 has been widely discussed since the start of the SARS-CoV-2 pandemic, when initial descriptions of patients...

cdc.gov

Clinical Questions about COVID-19: Questions and Answers

Source: US CDC

Updated: Clinical Questions about COVID-19 - Questions and Answers.

cdc.gov

Toolkit for Pregnant People and New Parents

Source: US CDC

Resources and tools to help pregnant people, breastfeeding people and new parents caring for infants to protect their health and help people who serve these communities communicate with them.

who.int

World Pharmacopoeias support public health during COVID-19 pandemic

Source: WHO

A pharmacopoeia is a legally-binding collection of standards and quality specifications for medical products. The WHO organizes official meetings entitled International Meeting of World Pharmacopoeias for participation of all WHO...

jwatch.org

COVID-19: Higher Mortality with B.1.1.7 Variant / Acute Kidney Injury / Bamlanivimab + Etesevimab

Source: NEJM

Report on peer review article A study on the increased risk to patients already suffering from kidney disease, the higher mortality rates caused by the B1.1.7 variant and the effective...

jwatch.org

Initiate Venous Thromboembolism Prophylaxis Early for Patients Hospitalized with COVID-19

Source: NEJM

Report on peer review article Although thromboses occur frequently in patients with COVID-19, and guidelines recommend pharmacologic prophylaxis, ongoing clinical trials will help determine the most appropriate anticoagulation dosing, as...

jwatch.org

Tocilizumab for Management of COVID-19: Finally (Some) Clarity

Source: NEJM

Report on peer pre release article Of all the medical interventions considered for management of severe or critical COVID-19, tocilizumab has been one of the most disputed. This agent seems...

thelancet.com

Interleukin-1 and interleukin-6 inhibition in patients with COVID-19 and hyperinflammation

Source: The Lancet

Report on peer reviewed article This article compares the clinical effectiveness of IL-1 inhibition (anakinra) and IL-6 inhibition (tocilizumab or sarilumab) with standard treatment in a large homogeneous cohort of...

thelancet.com

Alternatives to conventional hospitalisation that enhance health systems’ capacity to treat COVID-19

Source: The Lancet

Opinion piece The deployment of alternative outpatient models in a specific setting should be planned and evaluated; therefore, further information on the cost-effectiveness of these models is warranted, as it...

thelancet.com

Enoxaparin is associated with lower rates of mortality than unfractionated Heparin in hospitalized COVID-19 patients

Source: The Lancet

Peer review article Although anticoagulants such as unfractionated Heparin and Enoxaparin are both being used for therapeutic mitigation of COVID associated coagulopathy (CAC), differences in their clinical outcomes remain to...

bmj.com

Severe COVID-19 pneumonia: pathogenesis and clinical management

Source: BMJ

Peer reviewed article Dexamethasone treatment improves mortality for the treatment of severe and critical COVID-19, while remdesivir may have modest benefit in time to recovery in patients with severe disease...

thelancet.com

Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial

Source: Lancet

Peer review article A small study concluded there was no significant difference in the proportion of patients alive and off oxygen therapy at day 14 whether they took mavrilimumab, although...

thelancet.com

Malnutrition risk in hospitalised COVID-19 patients receiving CPAP

Source: Lancet

Report on peer reviewed article It is recommended that health-care professionals with expertise in nutrition, especially dietitians, nutrition nurses, physicians, and pharmacists, should be engaged in the assessment and care...

bmj.com

What is my COVID risk?

Source: BMJ

An article aimed at doctors with an aim to consider an individual's risk from COVID-19 in two parts; the risk of catching it and the risk of poor outcome if...

nice.org.uk

COVID-19 rapid guideline: managing COVID-19

Source: NICE

This guideline covers the management of COVID-19 for children, young people and adults in all care settings. It brings together our existing recommendations on managing COVID-19 so that healthcare staff...

thelancet.com

Convalescent plasma from people vaccinated after COVID-19 infection

Source: The Lancet

Opinion piece Plasma collected from previously infected people to passively transfer antibodies to protect or treat humans (convalescent plasma), has been successfully used since the late 19th century to treat...

thelancet.com

COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study

Source: The Lancet

Peer review article Rituximab therapy is associated with more severe COVID-19. Rituximab will have to be prescribed with particular caution in patients with inflammatory rheumatic and musculoskeletal diseases.

who.int

Type 1 diabetes and recovered from COVID-19 symptoms: Khadija’s story

Source: WHO

A personal account about the effects of COVID-19 on a type-1 diabetes sufferer.

jwatch.org

Prophylaxis Against Venous Thromboembolism in ICU Patients with COVID-19

Source: NEJM

Report on peer reviewed article With the high frequency of venous thromboembolism (VTE) in patients with COVID-19, it would make sense that higher-dose VTE prophylaxis would lead to better outcomes;...

jwatch.org

Outcomes of COVID-19 in Patients with Multiple Sclerosis

Source: NEJM

Report on peer reviewed article In addition to the risk factors for COVID-19 severity seen for the general population, MS disability level is also a substantial factor.

nice.org.uk

COVID-19 rapid guideline: rheumatological autoimmune, inflammatory and metabolic bone disorders

Source: NICE

The purpose of this guideline is to maximise the safety of children and adults with rheumatological autoimmune, inflammatory and metabolic bone disorders during the COVID-19 pandemic, while protecting staff from...

thelancet.com

The role of antirheumatics in patients with COVID-19

Source: The Lancet

Peer review article Evidence on the use of other anti-rheumatic drugs, including C5a inhibitors and intravenous immunoglobulin, suggest some potential benefit, but large adequately powered clinical trials are urgently needed....

thelancet.com

Association between pre-existing respiratory disease and its treatment, and severe COVID-19: a population cohort study

Source: The Lancet

Peer review article The risk of severe COVID-19 in people with asthma is relatively small. People with COPD and interstitial lung disease appear to have a modestly increased risk of...

bmj.com

Guidance for the design and reporting of studies evaluating the clinical performance of tests for present or past SARS-CoV-2 infection

Source: BMJ

More than 1700 preprints and peer reviewed journal articles evaluating tests for SARS-CoV-2 infection have been published as of January 2021. However, evaluations of these studies have identified many methodological...

bmj.com

A living WHO guideline on drugs for covid-19

Source: BMJ

This is the fourth version (update 3) of the living guideline which provides the latest scientific advice covering drugs treatments for COVID-19.  .

bmj.com

Drug treatments for covid-19: living systematic review and network meta-analysis

Source: BMJ

Meta-analysis of peer review articles on  drugs treatments for COVID-19.

bmj.com

World leaders call for urgent action on adolescent wellbeing

Source: BMJ

Governments and health leaders across the world have published a rallying cry for urgent global action to improve adolescent wellbeing. They highlight that even before covid-19 adolescents and young adults...

cdc.gov

Science Brief: Evidence used to update the list of underlying medical conditions that increase a person’s risk of severe illness from COVID-19

Source: US CDC

Updates to the list of underlying medical conditions that put adults of any age at high risk for severe illness from the virus that causes COVID-19 were based on evidence...

who.int

WHO Director-General and global faith leaders high-level dialogue on COVID-19

Source: WHO

In addition to discussion around vaccine access, equity and acceptance the senior religious leaders shared with Dr. Tedros their collective experiences, including:  Efforts to bridge the gap between science and...

who.int

WHO advises that ivermectin only be used to treat COVID-19 within clinical trials

Source: WHO

The current evidence on the use of ivermectin to treat COVID-19 patients is inconclusive. Until more data is available, WHO recommends that the drug only be used within clinical trials....

who.int

Living with the Times: new toolkit helps older adults maintain good mental health and wellbeing during the COVID-19 pandemic.

Source: WHO

The “Living with the Times” toolkit contains illustrated posters with key messages for older adults on how to maintain their well-being during the COVID-19 pandemic, while supporting those around them....

afro.who.int

South Sudan: African Development Bank and WHO enhance COVID-19 case management

Source: WHO Africa

The African Development Bank and WHO have delivered essential medical supplies, including intensive care unit (ICU) beds, medicines, lifesaving biomedical equipment and personal protective equipment (PPE) to South Sudan’s Ministry...

jwatch.org

VTE Risk in Outpatients with COVID-19

Source: NEJM

Report on peer review article This study suggests that outpatients with COVID-19 do not have excess venous thromboembolism (VTE) risk and argues against routine pharmacologic VTE prophylaxis for outpatients with...

nejm.org

Preparing for the Future — Nanobodies for Covid-19?

Source: NEJM

Researchers immunized alpacas and llamas with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein and identified nanobodies that specifically bind to the receptor-binding domain (RBD) of the virus...

nice.org.uk

COVID-19 rapid guideline: gastrointestinal and liver conditions treated with drugs affecting the immune response

Source: NICE

The purpose of this guideline is to maximise the safety of children and adults who have gastrointestinal or liver conditions treated with drugs affecting the immune response during the COVID...

nice.org.uk

COVID-19 rapid guideline: dermatological conditions treated with drugs affecting the immune response

Source: NICE

The purpose of this guideline is to maximise the safety of children and adults who have dermatological conditions treated with drugs affecting the immune response during the COVID-19 pandemic.

thelancet.com

A randomized, double-blind, placebo-controlled phase 1 trial of inhaled and intranasal niclosamide: A broad spectrum antiviral candidate for treatment of COVID-19

Source: The Lancet

Peer review article A formulation of niclosamide, a potent anti-SARS-CoV-2 agent and a broad-spectrum antiviral treatment candidate, optimized for inhalation and intranasal administration (UNI91104) was developed. UNI91104, a promising candidate...

thelancet.com

Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial

Source: The Lancet

Peer review article Early administration of inhaled budesonide reduced the likelihood of needing urgent medical care and reduced time to recovery after early COVID-19.

thelancet.com

Early treatment with inhaled budesonide to prevent clinical deterioration in patients with COVID-19

Source: The Lancet

Report on peer review article Ongoing randomised clinical trials using other inhaled corticosteroids or exploring the effects of budesonide in more severe (hospitalised) COVID-19 patients continue. Observations that clinical recovery...

nhs.uk

How to treat coronavirus symptoms at home

Source: NHS

This summarises how people can ease symptoms of COVID-19 at home. For a fever, one should rest and drink plenty of fluids, and one may take paracetamol or ibuprofen. For...

ebm.bmj.com

Inactivated trivalent influenza vaccination is associated with lower mortality among patients with COVID-19 in Brazil

Source: BMJ

A study in Brazil of over 50000 patients hospitalised with COVID-19 found that patients who had received inactivated trivalent influenza vaccine in 2020 had significantly higher chances of surviving and...

nice.org.uk

COVID-19 rapid guideline: vitamin D

Source: National Institute for Health and Care Excellence (NICE)

Low vitamin D status has been associated with more severe COVID-19 outcomes, however there is not enough evidence to say that more severe COVID-19 outcomes have been caused by low...

thelancet.com

Vitamin D and COVID-19: why the controversy?

Source: The Lancet

There is a lot of debate on whether vitamin D supplements have an effect on respiratory tract infections in general and more recently on COVID-19. Results from trials pre-pandemic vary....

bestpractice.bmj.com

Emerging treatments

Source: BMJ

This is a chapter in a large document giving an overview of COVID-19. This section describes many emerging treatments. This summary highlights selected potential treatments listed in the article: -...

cdc.gov

Potential treatments

Source: CDC

The FDA has approved remdesivir to treat COVID-19 and has issued emergency use authorisations (EUAs) for certain other drugs for the treatment of COVID-19. People who test positive for COVID-19...

bmj.com

Drug treatments for covid-19: living systematic review and network meta-analysis

Source: BMJ

This is a living review of current evidence for COVID-19 treatments and is therefore updated regularly with new data. Since it was first published in July 2020, it has been...

bmj.com

Covid-19: What now for remdesivir?

Source: BMJ

Remdesivir is an antiviral which was developed in a collaboration between Gilead Sciences, a biopharmaceutical company, and the US Centers for Disease Control and Prevention (CDC) and US Army Medical...

england.nhs.uk

Interim Position Statement: Interleukin-6 inhibitors (tocilizumab or sarilumab) for patients admitted to ICU with COVID-19 pneumonia (adults)

Source: NHS

Patients may be considered for treatment with tocilizumab or sarilumab if they are infected with COVID-19 and admitted into intensive care and require respiratory support. There are several criteria for...

bmj.com

Covid-19: FDA authorises neutralising antibody bamlanivimab for non-admitted patients

Source: BMJ

The US Food and Drug Administration has issued an Emergency Use Authorisation (EUA) for the use of bamlanivimab to treat patients with mild-to-moderate COVID-19. Clinical trials have shown that bamlanivimab...

ecdc.europa.eu

Vaccines and treatment of COVID-19

Source: European Centre for Disease Prevention and Control (ECDC)

This article summarises some of the main pharmaceuticals emerging as potential treatment or prophylaxis and is updated as new information arrives. In many cases, trials are ongoing: - Dexamethasone: studies...

thelancet.com

Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Source: The Lancet

A trial on 5040 hospitalised COVID-19 patients found that treatment with lopinavir–ritonavir did not lead to reduced mortality, nor did it affect length of hospitalisation or progression of the disease.

nejm.org

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19

Source: New England Journal of Medicine

This study describes the results of a double-blind, randomized, placebo-controlled trial evaluating the use of baricitinib plus remdesivir in treating 1033 adults hospitalised with COVID-19. The study found that baricitinib...

bmj.com

Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)

Source: BMJ

A trial on 464 adults with moderate COVID-19 found that convalescent plasma (blood plasma from donors who have recovered from COVID-19) is not effective in reducing mortality or progression to...

nejm.org

A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia

Source: New England Journal of Medicine

Convalescent plasma is blood plasma from donors who have recovered from COVID-19. A trial of 333 patients with severe COVID-19 pneumonia found that there were no significant difference in the...

africacdc.org

COVID-19 Scientific and Public Health Policy Update – (01 December 2020)

Source: Africa CDC

This update provides a summary of the latest developments in scientific knowledge and public health policy from around the world. Highlights on treatments are summarised below: - A small trial...

africacdc.org

COVID-19 Scientific and Public Health Policy Update – (15 December 2020)

Source: Africa CDC

This update provides a summary of the latest developments in scientific knowledge and public health policy from around the world. Highlights on treatments are summarised below: - A study looked...

who.int

Therapeutics and COVID-19: living guideline

Source: WHO

This is a living guideline containing information and recommendations on some treatment options. Guidelines are based on evidence from clinical trials and scientific publications. It is expected that the guidelines...

africacdc.org

Joint WHO AFRO and Africa CDC Statement on the Use of Corticosteroid for the Management of Severe and Critical COVID-19 Cases

Source: Africa CDC

Africa CDC and the WHO have published guidelines on the use of corticosteroid for managing severe and critical COVID-19 patients. The major recommendations are to use corticosteroids (such as dexamethasone...

kemri.org

Prevention Measures; If You Are Sick; Caring for Someone at Home

Source: Kenya Medical Research Institute

This resource from the Kenya Medical Research Institute allows you to toggle between guidance on various subtopics related to COVID-19, from prevention, to managing illness, and looking after someone who...

nutrition.bmj.com

No evidence that vitamin D is able to prevent or affect the severity of COVID-19 in individuals with European ancestry: a Mendelian randomisation study of open data

Source: BMJ

This study found no evidence that vitamin D is protective against SARS-CoV-2 infection or COVID-19 severity. The data support the recent statement by the National Institute for Health and Care...

bestpractice.bmj.com

Coronavirus disease 2019 (COVID-19) Recommendations

Source: BMJ

This BMJ article recommends that management of COVID cases should be based on disease severity and must focus on: isolation at a suitable location, infection prevention and control measures, symptom...

bestpractice.bmj.com

Coronavirus disease 2019 (COVID-19) Primary Prevention

Source: BMJ

An article aggregating data / studies, providing six recommendations for the general public: 1) washing hands often with soap and water for at least 20 seconds or an alcohol-based hand...

jwatch.org

COVID-19 and Thromboembolism Prophylaxis: Is More Anticoagulation Better?

Source: NEJM

Report on research article COVID-19 and Thromboembolism Prophylaxis: Is More Anticoagulation Better? Research suggests that more anticoagulation is not necessarily better -- two reports indicate no statistical differences between dosing...

jwatch.org

COVID-19: ID Group Recommends Tocilizumab / Layperson Phone Calls / Pooled Testing Benefits

Source: NEJM

The Infectious Diseases Society of America (IDSA) now suggests adding the interleukin-6 inhibitor tocilizumab to standard care.

jwatch.org

Our Latest Coverage of COVID-19

Source: NEJM

Presentation of the week's summaries, commentary, and news on the pandemic. This week, NEJM Journal Watch covered COVID-19–related topics including limitations of procalcitonin for antimicrobial stewardship, efficacy of mRNA vaccines...

jwatch.org

COVID-19: Reinfections / New Name for “Long COVID” / IL-6 Inhibitor / NYC & Calif. Variants

Source: NEJM

Report on research articles COVID-19 reinfections confirmed in US; Interleukin-6 (a protein linked to inflammation) inhibitors as a promising therapy for COVID-19 and; further information on the spread of variants.

nejm.org

Dexamethasone in Hospitalized Patients with Covid-19

Source: NEJM

Peer reviewed article In patients hospitalized with COVID-19, the use of dexamethasone resulted in lower 28-day mortality among those who were receiving either invasive mechanical ventilation or oxygen alone at...

nejm.org

Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19

Source: NEJM

Peer reviewed article Critically ill patients with COVID-19 receiving organ support in ICUs, treatment with the interleukin-6 receptor antagonists tocilizumab and sarilumab displayed improved outcomes, including survival.

thelancet.com

COVID-19 drug practices risk antimicrobial resistance evolution

Source: The Lancet

Opinion piece There was an increasing demand for and misuse of various drugs in the treatment of COVID-19 irrespective of paucity of scientific evidence. This could lead to a speedier...

cdc.gov

Clinical Questions about COVID-19: Questions and Answers

Source: US CDC

Brief summaries of clinical questions and answers on topics relating to COVID-19, including: COVID-19 Risk, Who is at Risk, Infection Control, Transmission, Testing, Diagnosis, and more.

cdc.gov

Global Clinical Mitigation

Source: US CDC

Clinical mitigation encompasses strategies to ensure adequate provision of care for mildly to moderately ill COVID-19 patients, and delivery of other non-COVID-19 essential health services during the COVID-19 outbreak.

cdc.gov

For Parents: Multisystem Inflammatory Syndrome in Children (MIS-C) associated with COVID-19

Source: US CDC

Multisystem inflammatory syndrome in children (MIS-C) is a condition where different body parts can become inflamed, including the heart, lungs, kidneys, brain, skin, eyes, or gastrointestinal organs. Many children with...

cdc.gov

Independent Evaluation of SARS-CoV-2 Antibody Test Performance

Source: US CDC

Serology tests play an important role in assessing the immune response to a previous SARS-CoV-2 infection, the virus that causes COVID-19. Evaluation of serology tests with well-characterized clinical samples (serum...

snopes.com

The COVID-19 vaccine is not recommended for pregnant women unless they are at high risk of exposure

Source: Snopes

Claim: The World Health Organisation warned that pregnant women should avoid the COVID-19 vaccination. Partly true As of January 2021, the World Health Organization (WHO) said that the use of...

nejm.org

Last-Mile Logistics of Covid Vaccination — The Role of Health Care Organizations

Source: New England Journal of Medicine

Opinion piece by Thomas H. Lee, M.D., and Alice H. Chen, M.D., M.P.H. This work of distributing the vaccine is compared with managing the last mile in other business sectors:...

nice.org.uk

COVID-19 rapid evidence summary: Sarilumab for COVID-19

Source: NICE

This evidence summary includes 1 prepublication study only, with a small number of patients randomised to sarilumab (n=48). This means that the findings may change if further evidence becomes available....

bmj.com

Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial

Source: BMJ

Tocilizumab is a treatment approved for the treatment of rheumatoid arthritis, giant cell arteritis and cytokine release syndrome. A gold standard, double blind, randomised control trial on 129 patients with...

who.int

Scientists tackle vaccine safety, efficacy and access at global R&D forum

Source: WHO

More than 2,800 scientists from 130 countries gathered on Friday (January 15) in a virtual forum hosted by the World Health Organization (WHO) to identify knowledge gaps and set research...

jwatch.org

Are Anti-SARS-CoV-2 Monoclonal Antibodies Beneficial for Outpatients with COVID-19?

Source: NEJM

Summary Review  Despite the lack of adjustment for the numerous comparisons in this study, bamlanivimab did not result in an improved virologic response at 11 days compared with placebo —...

jwatch.org

COVID-19: Guidance on Tocilizumab / Asymptomatic Testing

Source: NEJM

Review  The National Institutes of Health has slightly upgraded tocilizumab as a treatment for COVID-19 in its latest COVID-19 treatment guidelines. Previously, the group recommended against the use of tocilizumab...

jwatch.org

COVID-19: Methylprednisolone for MIS-C / Younger Adults / Access to Monoclonal Antibodies

Source: NEJM

Review by By Kelly Young Adding methylprednisolone to intravenous immunoglobulins (IVIG - chemicals made by our immune systems to fight the virus) is associated with better fever outcomes in multisystem...

jwatch.org

Are Anti-SARS-CoV-2 Monoclonal Antibodies Beneficial for Outpatients with COVID-19?

Source: NEJM

For reducing viral load (the number of virus particles in a patient’s test sample), a combination of two anti-SARS-CoV-2 monoclonal antibodies (lab made, but identical to the immune system proteins...

thelancet.com

The potential of rapalogs to enhance resilience against SARS-CoV-2 infection and reduce the severity of COVID-19

Source: The Lancet

Opinion piece  The piece explores the potential of rapalogs (drugs used to suppress cancer) to enhance resilience against SARS-CoV-2 infection and reduce the severity of COVID-19. SARS-CoV-2 affects old people...

thelancet.com

Application of unsupervised machine learning to identify and characterise hydroxychloroquine misinformation on Twitter

Source: The Lancet

Opinion piece  Concerns about hydroxychloroquine's safety and efficacy are well documented, including its association with cardiac adverse events, blood and lymph system disorders, liver problems, and kidney injury. A study...

thelancet.com

WHO international non-proprietary names: the need to distinguish COVID-19 vaccines

Source: The Lancet

Opinion piece  The WHO International Non-proprietary Names Programme would like to highlight that international non-proprietary names (INNs), assigned to well defined pharmaceutical substances, including those used in vaccines, ensure that...

thelancet.com

The impact of the COVID-19 lockdown on HIV care in 65 South African primary care clinics: an interrupted time series analysis

Source: The Lancet

ART (Anti-retroviral treatment - the most effective method of countering HIV) provision was generally maintained during the 2020 COVID-19 lockdown, but HIV testing and ART initiations were heavily impacted. Strategies...

thelancet.com

Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial

Source: The Lancet

To date, only monoclonal antibodies (antibodies made in laboratories but identical to the ones our white blood cells produce) have been shown to be effective for outpatients with COVID-19. Interferon...

bmj.com

Why aren’t covid-19 vaccines being manufactured in standard prefilled syringes?

Source: BMJ

Opinion piece  This article discusses the difficulties of the final processes when delivering vaccines. It questions why, -given prefilled syringes are the safest and standard recommended delivery device for most...

bmj.com

Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant

Source: BMJ

News article  The SARS-CoV-2 vaccine produced by the US biotechnology company Novavax is 95.6% effective against the original variant of SARS-CoV-2 but also provides protection against the newer variants B.1.1.7...

afro.who.int

COVAX expects to start sending millions of COVID-19 vaccines to Africa in February

Source: Afro WHO

COVAX has notified countries in Africa of the estimated dose allocation for the first phase of COVID-19 vaccine delivery. The global initiative led by the WHO, Gavi the Vaccine Alliance...